Karen H. Lu, MD, on Delivering Online, Accessible Genetic Testing

Video

The expert discussed study methods and results from the MAGENTA trial evaluating pre and/or post-test genetic counseling.

At the 2020 ASCO Virtual Scientific Program, Karen H. Lu, MD, from the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, presented on findings from the MAGENTA trial, designed to test whether pre and/or post-test genetic counseling is needed to optimally deliver online accessible genetic testing.

She spoke to CancerNetwork about the methods of their study, as well as its results.

Transcription:

So the women would watch a video. And the video would explain to them what is involved in genetic testing, what the information can tell them, and also what the limitations of that information is. There were 4 different groups. Half of the group had pre-test genetic testing, with a live human being. So we consider that standard of care. And then the other half just got the educational videos.

So we found that so our primary end point was looking at distress at 3 months. And we wanted to see if there is more distress in individuals who go through a process that involves less kind of person-to-person counseling, whether that be pre-test counseling or post-test counseling, and we actually found no difference between any of the groups. So that showed us that delivering genetic counseling through this electronic platform and getting the results back in that same way, did not cause increased distress in these women who underwent genetic testing.

Recent Videos
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
Related Content